Qin Yan

List of Publications by Year
in descending order

71 papers	5,944 citations	87723 38 h-index	88477 70 g-index
83 all docs	83 docs citations	83 times ranked	8481 citing authors

#	Article	IF	Citations
1	CECR2 drives breast cancer metastasis by promoting NF-ÎºB signaling and macrophage-mediated immune suppression. Science Translational Medicine, 2022, 14, eabf5473.	5.8	51
2	Tick tock, tick tock: Mouse culture and tissue aging captured by an epigenetic clock. Aging Cell, 2022, 21, e13553.	3.0	19
3	Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis. Nature Communications, 2022, 13, 898.	5.8	19
4	Awakening KDM5B to defeat leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2202245119.	3.3	0
5	Editorial: Epigenetic Regulation and Tumor Immunotherapy. Frontiers in Oncology, 2022, 12, .	1.3	2
6	Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection. Cell, 2021, 184, 76-91.e13.	13.5	418
7	5â€Fluorouracil efficacy requires antiâ€tumor immunity triggered by cancerâ€cellâ€intrinsic STING. EMBO Journal, 2021, 40, e106065.	3.5	44
8	KDM2B promotes cell viability by enhancing DNA damage response in canine hemangiosarcoma. Journal of Genetics and Genomics, 2021, 48, 618-630.	1.7	13
9	The roles of epigenetics in cancer progression and metastasis. Biochemical Journal, 2021, 478, 3373-3393.	1.7	26
10	KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements. Nature, 2021, 598, 682-687.	13.7	117
11	DNA methylation markers in esophageal cancer: an emerging tool for cancer surveillance and treatment. American Journal of Cancer Research, 2021, 11, 5644-5658.	1.4	1
12	MAL2 mediates the formation of stable HER2 signaling complexes within lipid raft-rich membrane protrusions in breast cancer cells. Cell Reports, 2021, 37, 110160.	2.9	12
13	Cancer progression is mediated by proline catabolism in non-small cell lung cancer. Oncogene, 2020, 39, 2358-2376.	2.6	51
14	Acquired Resistance to HER2-Targeted Therapies Creates Vulnerability to ATP Synthase Inhibition. Cancer Research, 2020, 80, 524-535.	0.4	26
15	KDM5B Is Essential for the Hyperactivation of PI3K/AKT Signaling in Prostate Tumorigenesis. Cancer Research, 2020, 80, 4633-4643.	0.4	32
16	Multi-Omics Investigation of Innate Navitoclax Resistance in Triple-Negative Breast Cancer Cells. Cancers, 2020, 12, 2551.	1.7	12
17	Specific chromatin landscapes and transcription factors couple breast cancer subtype with metastatic relapse to lung or brain. BMC Medical Genomics, 2020, 13, 33.	0.7	23
18	Annotation and cluster analysis of long noncoding RNA linked to male sex and estrogen in cancers. Npj Precision Oncology, 2020, 4, 5.	2.3	14

#	Article	IF	Citations
19	Cancer Epigenetics, Tumor Immunity, and Immunotherapy. Trends in Cancer, 2020, 6, 580-592.	3.8	166
20	Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction. Nature Communications, 2020, 11, 1833.	5.8	100
21	GIAT4RA functions as a tumor suppressor in non-small cell lung cancer by counteracting Uchl3â€“mediated deubiquitination of LSH. Oncogene, 2019, 38, 7133-7145.	2.6	39
22	LSH interacts with and stabilizes GINS4 transcript that promotes tumourigenesis in non-small cell lung cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 280.	3.5	35
23	Oxygen sensing and adaptability won the 2019 Nobel Prize in Physiology or medicine. Genes and Diseases, 2019, 6, 328-332.	1.5	44
24	Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer. Scientific Reports, 2019, 9, 14934.	1.6	19
25	Long noncoding RNA LINC00336 inhibits ferroptosis in lung cancer by functioning as a competing endogenous RNA. Cell Death and Differentiation, 2019, 26, 2329-2343.	5.0	365
26	PBRM1 acts as a p53 lysine-acetylation reader to suppress renal tumor growth. Nature Communications, 2019, 10, 5800.	5.8	47
27	Mitochondrial DNA stress signalling protects the nuclear genome. Nature Metabolism, 2019, 1, 1209-1218.	5.1	87
28	High affinity binding of H3K14ac through collaboration of bromodomains 2, 4 and 5 is critical for the molecular and tumor suppressor functions of <scp>PBRM</scp>1. Molecular Oncology, 2019, 13, 811-828.	2.1	22
29	KDM5B Promotes Drug Resistance by Regulating Melanoma-Propagating Cell Subpopulations. Molecular Cancer Therapeutics, 2019, 18, 706-717.	1.9	45
30	Neuronal calcium sensor 1 (NCS1) promotes motility and metastatic spread of breast cancer cells in vitro and in vivo. FASEB Journal, 2019, 33, 4802-4813.	0.2	14
31	The multiplexed CRISPR targeting platforms. Drug Discovery Today: Technologies, 2018, 28, 53-61.	4.0	9
32	Insights into the Action of Inhibitor Enantiomers against Histone Lysine Demethylase 5A. Journal of Medicinal Chemistry, 2018, 61, 3193-3208.	2.9	9
33	KDM5A Regulates a Translational Program that Controls p53 Protein Expression. IScience, 2018, 9, 84-100.	1.9	25
34	KDM5 histone demethylases repress immune response via suppression of STING. PLoS Biology, 2018, 16, e2006134.	2.6	106
35	Multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer. ELife, 2018, 7, .	2.8	25
36	The KDM5 family is required for activation of pro-proliferative cell cycle genes during adipocyte differentiation. Nucleic Acids Research, 2017, 45, 1743-1759.	6.5	49

#	Article	IF	Citations
37	Cell Division Cycle 42 plays a Cell type-Specific role in Lung Tumorigenesis. Scientific Reports, 2017, 7, 10407.	1.6	9
38	The Molecular Basis of Histone Demethylation. Cancer Drug Discovery and Development, 2017, , 151-219.	0.2	8
39	EGLN1/c-Myc Induced Lymphoid-Specific Helicase Inhibits Ferroptosis through Lipid Metabolic Gene Expression Changes. Theranostics, 2017, 7, 3293-3305.	4.6	199
40	KDM5 lysine demethylases are involved in maintenance of 3â€²UTR length. Science Advances, 2016, 2, e1501662.	4.7	23
41	An easy and efficient inducible CRISPR/Cas9 platform with improved specificity for multiple gene targeting. Nucleic Acids Research, 2016, 44, gkw660.	6.5	158
42	Structural Basis for KDM5A Histone Lysine Demethylase Inhibition by Diverse Compounds. Cell Chemical Biology, 2016, 23, 769-781.	2.5	80
43	Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance. Oncotarget, 2016, 7, 39931-39944.	0.8	71
44	High-throughput screening to identify inhibitors of lysine demethylases. Epigenomics, 2015, 7, 57-65.	1.0	16
45	Histone Demethylase Jumonji AT-rich Interactive Domain 1B (JARID1B) Controls Mammary Gland Development by Regulating Key Developmental and Lineage Specification Genes. Journal of Biological Chemistry, 2014, 289, 17620-17633.	1.6	48
46	Significance of glioma-associated oncogene homolog 1 (GLI1)expression in claudin-low breast cancer and crosstalk with the nuclear factor kappa-light-chain-enhancer of activated B cells (NFÎºB) pathway. Breast Cancer Research, 2014, 16, 444.	2.2	58
47	Histone Demethylase RBP2 Is Critical for Breast Cancer Progression and Metastasis. Cell Reports, 2014, 6, 868-877.	2.9	97
48	Identification of Small Molecule Inhibitors of Jumonji AT-rich Interactive Domain 1B (JARID1B) Histone Demethylase by a Sensitive High Throughput Screen. Journal of Biological Chemistry, 2013, 288, 9408-9417.	1.6	115
49	Histone Demethylase RBP2 Promotes Lung Tumorigenesis and Cancer Metastasis. Cancer Research, 2013, 73, 4711-4721.	0.4	138
50	Histone Demethylases Set the Stage for Cancer Metastasis. Science Signaling, 2013, 6, pe15, 1-2.	1.6	10
51	Coordinated repression of cell cycle genes by KDM5A and E2F4 during differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 18499-18504.	3.3	67
52	The von Hippelâ€“Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C. Oncogene, 2012, 31, 776-786.	2.6	133
53	Epigenetic Mechanisms in Commonly Occurring Cancers. DNA and Cell Biology, 2012, 31, S-49-S-61.	0.9	31
54	Histone Ubiquitination and Deubiquitination in Transcription, DNA Damage Response, and Cancer. Frontiers in Oncology, 2012, 2, 26.	1.3	225

#	Article	IF	Citations
55	Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 13379-13386.	3.3	143
56	Epigenetic Regulation by Lysine Demethylase 5 (KDM5) Enzymes in Cancer. Cancers, 2011, 3, 1383-1404.	1.7	136
57	Exploiting cellular senescence to treat cancer and circumvent drug resistance. Cancer Biology and Therapy, 2010, 9, 166-175.	1.5	21
58	A Role for Mammalian Sin3 in Permanent Gene Silencing. Molecular Cell, 2008, 32, 359-370.	4.5	112
59	Hypoxia-Inducible Factor Linked to Differential Kidney Cancer Risk Seen with Type 2A and Type 2B VHL Mutations. Molecular and Cellular Biology, 2007, 27, 5381-5392.	1.1	102
60	The Retinoblastoma Binding Protein RBP2 Is an H3K4 Demethylase. Cell, 2007, 128, 889-900.	13.5	399
61	pVHL Acts as an Adaptor to Promote the Inhibitory Phosphorylation of the NF-ÎºB Agonist Card9 by CK2. Molecular Cell, 2007, 28, 15-27.	4.5	163
62	The Hypoxia-Inducible Factor 2Î± N-Terminal and C-Terminal Transactivation Domains Cooperate To Promote Renal Tumorigenesis In Vivo. Molecular and Cellular Biology, 2007, 27, 2092-2102.	1.1	172
63	Both BC-Box Motifs of Adenovirus Protein E4orf6 Are Required To Efficiently Assemble an E3 Ligase Complex That Degrades p53. Molecular and Cellular Biology, 2004, 24, 9619-9629.	1.1	91
64	Identification of Elongin C and Skp1 Sequences That Determine Cullin Selection. Journal of Biological Chemistry, 2004, 279, 43019-43026.	1.6	10
65	MUF1, A Novel Elongin BC-interacting Leucine-rich Repeat Protein That Can Assemble with Cul5 and Rbx1 to Reconstitute a Ubiquitin Ligase. Journal of Biological Chemistry, 2001, 276, 29748-29753.	1.6	135
66	Transcription Factors TFIIF, ELL, and Elongin Negatively Regulate SII-induced Nascent Transcript Cleavage by Non-arrested RNA Polymerase II Elongation Intermediates. Journal of Biological Chemistry, 2001, 276, 23109-23114.	1.6	35
67	Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes and Development, 2001, 15, 3104-3117.	2.7	418
68	A Role for the TFIIH XPB DNA Helicase in Promoter Escape by RNA Polymerase II. Journal of Biological Chemistry, 1999, 274, 22127-22130.	1.6	77
69	Dual Roles for Transcription Factor IIF in Promoter Escape by RNA Polymerase II. Journal of Biological Chemistry, 1999, 274, 35668-35675.	1.6	65
70	The Rbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2. Genes and Development, 1999, 13, 2928-2933.	2.7	251
71	Mechanism of Promoter Escape by RNA Polymerase II. Cold Spring Harbor Symposia on Quantitative Biology, 1998, 63, 357-364.	2.0	7